

ASX Announcement

19 December 2025

ReNerve appoints Maja McGuire as Non-Executive Chair

ReNerve Limited (ASX, "ReNerve" or "the Company"), an Australian biotechnology company developing innovative products for peripheral nerve injury ("PNI") repair, is pleased to announce the appointment of Ms Maja McGuire as Non-Executive Chair of the Company's Board of Directors, effective immediately.

Ms McGuire was appointed to the ReNerve Board as a Non-Executive Director and interim chair on 4 December 2025 as part of the Company's Board renewal process. Her appointment as Chair reflects the Board's focus on strengthening governance, strategic oversight and leadership as ReNerve continues to progress its commercial and development programs.

Ms McGuire brings more than 15 years' experience across board and senior management roles, including as a Chair and Non-Executive Director of ASX-listed companies. She has extensive experience in corporate strategy, governance and listed-company advisory roles, with a background as General Counsel and Company Secretary in the medical device and life sciences sectors. Ms McGuire currently serves as Non-Executive Chair of TechGen Metals and as a Non-Executive Director of several ASX-listed companies.

***Ms McGuire said she was** "delighted to be joining ReNerve at a time when it is looking at strong growth and further development of its innovative technologies that makes significant quality of life interventions to patients suffering peripheral nerve damage"*

"We are very pleased to appoint Maja as Non-Executive Chair of ReNerve. Her experience in governance, corporate strategy and medical device companies will be highly valuable as the Company continues to execute on its commercial strategy and advance its development programs." **said CEO Dr Julian Chick.**

- ENDS -

This announcement has been approved for release by the Company's Board of Directors.

For further information and enquiries, please contact:

Dr Julian Chick
CEO & Managing Director
ReNerve Ltd
+61 (03) 9482 3940
info@renerve.com.au

Matthew Wright
Investor & Media Relations
NWR Communications
+61 (0) 451 896 420
matt@nwrcommunications.com.au



+61 (03) 9482 3940



157 Heidelberg Rd,
Northcote, VIC 3070



www.renerve.com.au

About ReNerve Limited (ASX:RNV)

ReNerve Limited (ASX:RNV) is transforming nerve repair and improving lives through breakthrough medical technology. Founded by a neurosurgeon and medtech researchers, ReNerve is a rapidly growing medical device company that has revolutionised peripheral nerve surgery with its innovative, ready-to-use solutions for peripheral nerve injuries (PNI). Our scientifically backed products are delivering measurably better outcomes for patients worldwide.

Proven Clinical Success

ReNerve's first flagship product, the FDA-cleared **NervAlign® Nerve Cuff**, is already making a dramatic difference in surgical outcomes across the United States. A recently announced clinical study has demonstrated remarkable results, showing that patients treated with the NervAlign® Nerve Cuff experienced post-surgical pain scores dropping from 7.1 to just 0.4, compared to from 7.1 to 3.3 without the device being used – a statistically significant improvement that's changing lives.

Comprehensive Product Portfolio

ReNerve is advancing a complete suite of nerve repair solutions:

- **NervAlign® Nerve Cuff** – Our bioabsorbable protective wrap, naturally absorbed within six months of surgery.
- **Deep Dermal tissue product** -- A unique deep dermal product used in the repair of reconstructive and cosmetic surgical cases.
- **Amniotic tissue product ranges** -- Three amniotic tissue product ranges used to aid the healing of wounds.
- **NervAlign® Nerve Conduit Range** – Next-generation nerve conduit leveraging advantages of eCOO technology in a material designed to facilitate nerve growth over short gaps between nerve ends.
- **NervAlign® Nerve Guide Matrix** – a customised and ready-to-use alternative to existing nerve grafts, for treatment of longer nerve gaps and more severe nerve injuries. It will eliminate the need for patients to undergo additional sural nerve harvesting.
- **NervAlign® Bionic Nerve** – Next-generation combination technology for the most challenging nerve repairs.

Market Leadership and Growth

With demonstrated market traction since the Company's 2022 product launch, ReNerve achieved 53% revenue growth in FY25, reaching \$271k in sales. Our high-margin, scalable products are positioning us as the go-to solution for surgeons seeking superior patient outcomes in the rapidly expanding global nerve repair market, valued at US\$1.6 billion in 2024 and is projected to reach \$6.2 billion by 2031.¹

¹ Global Nerve Repair Biomaterials Market Research Report (2020 – 2031)

Vision and Values

We're not just developing medical devices – we're engineering hope. By creating the ideal healing environment for nerve repair and regeneration, ReNerve bridges critical gaps in healthcare while empowering the human body's natural healing process. Our cleaner, safer, and more effective solutions represent the future of peripheral nerve surgery.